Dupixent (dupilumab) has been widely prescribed to treat conditions such as eczema, asthma, and chronic rhinosinusitis with nasal polyps, and COPD. While the drug has helped many people manage their symptoms, a growing body of evidence suggests that some patients have experienced serious side effects that have not been adequately disclosed by Dupixent’s manufacturers. Specifically, use of Dupixent has been linked to a higher risk of cutaneous T-cell lymphoma (CTCL). Multiple, recent studies have prompted legal action against the drug’s manufacturers, primarily Regeneron Pharmaceuticals and Sanofi, and law firms like Kershaw Talley Barlow are helping patients nationwide seek accountability.
Why People Are Filing Dupixent Lawsuits
Patients filing Dupixent lawsuits generally allege that the manufacturer failed to properly warn consumers and healthcare providers about the drug’s potential dangers, specifically the link to CTCL. The lawsuits claim that if patients had known the full scope of Dupixent’s risks, they may have chosen a different course of treatment or monitored their health more closely while using the prescription drug.
While individual circumstances vary, Dupixent lawsuits often involve:
- Unexpected or long-term side effects that caused lasting health complications, namely, cutaneous T-cell lymphoma.
- Alleged failures in the drug’s design or marketing, where warning signs of harm were not correctly shared with the public and medical community as a whole.
- Emotional and financial burdens stemming from medical treatment, lost work, and reduced quality of life.
Mass tort litigation allows affected claimants to pursue justice somewhat collectively. Although each case can succeed or fail under its own merits in a mass tort lawsuit, the arguments, evidence, and details of one specific case have the potential to strengthen another.
Reported Risks & Side Effects Associated with Dupixent Use
Dupixent works by suppressing parts of the immune system involved in inflammation. However, for some users, this mechanism can lead to adverse reactions.
One of the most severe and concerning risks is the link between Dupixent and cutaneous T-cell lymphoma. Symptoms of CTCL can include rashes, itching, swollen lymph nodes, tumors near the skin, and more. The greatest concern of this link is that it was undisclosed by the Big Pharma corporations that make and sell Dupixent, so patients and medical providers were not provided with adequate warnings.
Kershaw Talley Barlow Is Helping Dupixent Patients Take Action
Our trial attorneys and scientists at Kershaw Talley Barlow have extensive experience handling mass tort and pharmaceutical litigation, representing clients across the country in complex drug injury cases. We have already begun investigating and filing claims against the manufacturers of Dupixent on behalf of those who allege that using the drug caused them to develop cutaneous T-cell lymphoma, and we are here to help you determine if you can take legal action in pursuit of financial compensation and justice, too.
If you were diagnosed with CTCL after taking Dupixent, it’s important to speak with our legal team soon because statutes of limitations apply that could prevent you from starting a claim if you wait too long. As more patients come forward, we will continue to stand ready to demand accountability from Big Pharma.
To learn more about filing a Dupixent CTCL lawsuit or to speak with an attorney about your case, contact Kershaw Talley Barlow online or call (916) 520-6639 today for a free consultation.
[1].2501311025155.jpg)